Letter | Published:

Conversion of staphylococcal pathogenicity islands to CRISPR-carrying antibacterial agents that cure infections in mice

Nature Biotechnology volume 36, pages 971976 (2018) | Download Citation

Abstract

Staphylococcus aureus and other staphylococci continue to cause life-threatening infections in both hospital and community settings1,2,3. They have become increasingly resistant to antibiotics, especially β-lactams and aminoglycosides, and their infections are now, in many cases, untreatable. Here we present a non-antibiotic, non-phage method of treating staphylococcal infections by engineering of the highly mobile staphylococcal pathogenicity islands (SaPIs). We replaced the SaPIs' toxin genes with antibacterial cargos to generate antibacterial drones (ABDs) that target the infecting bacteria in the animal host, express their cargo, kill or disarm the bacteria and thus abrogate the infection. Here we have constructed ABDs with either a CRISPR–Cas9 bactericidal or a CRISPR–dCas9 virulence-blocking module. We show that both ABDs block the development of a murine subcutaneous S. aureus abscess and that the bactericidal module rescues mice given a lethal dose of S. aureus intraperitoneally.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc. Natl. Acad. Sci. USA 105, 1327–1332 (2008).

  2. 2.

    et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144, 309–317 (2006).

  3. 3.

    et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int. J. Antimicrob. Agents 39, 96–104 (2012).

  4. 4.

    , , , & The gene for toxic shock toxin is carried by a family of mobile pathogenicity islands in Staphylococcus aureus. Mol. Microbiol. 29, 527–543 (1998).

  5. 5.

    , , & Transducing particles of Staphylococcus aureus pathogenicity island SaPI1 are comprised of helper phage-encoded proteins. J. Bacteriol. 189, 7520–7524 (2007).

  6. 6.

    et al. Moonlighting bacteriophage proteins derepress staphylococcal pathogenicity islands. Nature 465, 779–782 (2010).

  7. 7.

    , & Molecular genetics of SaPI1—a mobile pathogenicity island in Staphylococcus aureus. Mol. Microbiol. 41, 365–377 (2001).

  8. 8.

    , & CRISPR/Cas9 in genome editing and beyond. Annu. Rev. Biochem. 85, 227–264 (2016).

  9. 9.

    & Quorum sensing in staphylococci. Annu. Rev. Genet. 42, 541–564 (2008).

  10. 10.

    , & Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc. Natl. Acad. Sci. USA 92, 12055–12059 (1995).

  11. 11.

    & Phage-mediated intergeneric transfer of toxin genes. Science 323, 139–141 (2009).

  12. 12.

    , , , & Pathogenicity island-directed transfer of unlinked chromosomal virulence genes. Mol. Cell 57, 138–149 (2015).

  13. 13.

    , , , & Hydrophobic interactions drive ligand-receptor recognition for activation and inhibition of staphylococcal quorum sensing. Proc. Natl. Acad. Sci. USA 101, 16168–16173 (2004).

  14. 14.

    , , , & Murine model of cutaneous infection with gram-positive cocci. Infect. Immun. 60, 2636–2640 (1992).

  15. 15.

    et al. DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 20, 2348–2357 (2002).

  16. 16.

    , , & Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 63, 1253–1264 (2011).

  17. 17.

    et al. Wall teichoic acid structure governs horizontal gene transfer between major bacterial pathogens. Nat. Commun. 4, 2345–2354 (2013).

  18. 18.

    et al. Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G+C content. J. Bacteriol. 186, 2862–2871 (2004).

  19. 19.

    , & Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8, 317–327 (2010).

  20. 20.

    et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. Natl. Acad. Sci. USA 96, 1218–1223 (1999).

  21. 21.

    , , , & Characteristics of lambda p4, a lambda derivative containing 9 per cent excess DNA. Virology 50, 373–380 (1972).

  22. 22.

    , , & Lambda replacement vectors carrying polylinker sequences. J. Mol. Biol. 170, 827–842 (1983).

  23. 23.

    , & Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32, 1141–1145 (2014).

  24. 24.

    et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32, 1146–1150 (2014).

  25. 25.

    Genetic systems in staphylococci. Methods Enzymol. 204, 587–636 (1991).

  26. 26.

    Abortive transduction of motility in Salmonella; a nonreplicated gene transmitted through many generations to a single descendant. J. Gen. Microbiol. 15, 575–598 (1956).

  27. 27.

    Chromosome fragments participating in transduction in Salmonella Typhimurium. Genetics 44, 457–470 (1959).

  28. 28.

    Transduction of chromosomal genes and episomes in Escherichia coli. Virology 11, 273–288 (1960).

Download references

Acknowledgements

This work was supported by NIH grant R01-AI22159 to RPN and by a grant-in-aid from NYU School of Medicine. The animal experiments described in this paper were conducted in conformity with all relevant ethical regulations, under IACUC protocol 160722-01, approved by the NYUSOM IACUC on 7/21/16.

Author information

Author notes

    • Geeta Ram

    Present address: Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, India.

    • Geeta Ram
    • , Hope F Ross
    •  & Richard P Novick

    These authors contributed equally to this work.

Affiliations

  1. Departments of Microbiology and Medicine, New York University School of Medicine, New York, New York, USA.

    • Geeta Ram
    • , Hope F Ross
    • , Richard P Novick
    • , Ivelisse Rodriguez-Pagan
    •  & Dunrong Jiang

Authors

  1. Search for Geeta Ram in:

  2. Search for Hope F Ross in:

  3. Search for Richard P Novick in:

  4. Search for Ivelisse Rodriguez-Pagan in:

  5. Search for Dunrong Jiang in:

Contributions

R.P.N., H.F.R. and G.R. planned and discussed the experiments. H.F.R. had the initial idea; G.R. and H.F.R. did the cloning; G.R. performed the in vitro tests; I.R.-P. and R.P.N. did the mouse experiments; D.J. did the DNA preparations; and R.P.N. did the microbiological work and wrote the manuscript.

Competing interests

A patent application has been filed by New York University, with G.R., H.F.R. and R.P.N. as inventors, on the basis of results presented in this paper.

Corresponding authors

Correspondence to Geeta Ram or Hope F Ross or Richard P Novick.

Supplementary information

PDF files

  1. 1.

    Supplementary Tables

    Supplementary Tables 1–4

  2. 2.

    Life Sciences Reporting Summary

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.4203